Peer-reviewed journal article highlights need for personalized, culturally relevant approaches to cognitive care and research BOSTON, June 2, 2025 /PRNewswire/…
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic…
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)…
Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today…
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing…
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting…
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two…
Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about…
Data presented by Delix Therapeutics at the 2025 American Society of Clinical Psychopharmacology (ASCP) Conference confirms the NeuLogiq® Platform is…
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom…